BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone45-0680-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30,000.00
Profitability
Miscellaneous
Employees10
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
BELLUS Health (OTCMKTS:BLUSF) Frequently Asked Questions
What is BELLUS Health's stock symbol?
BELLUS Health trades on the OTCMKTS under the ticker symbol "BLUSF."
How were BELLUS Health's earnings last quarter?
BELLUS Health Inc (OTCMKTS:BLUSF) released its earnings results on Thursday, August, 8th. The company reported ($0.04) EPS for the quarter. The business had revenue of $0.01 million for the quarter. BELLUS Health had a negative net margin of 49,910.34% and a negative return on equity of 48.37%. View BELLUS Health's Earnings History.
When is BELLUS Health's next earnings date?
Has BELLUS Health been receiving favorable news coverage?
News headlines about BLUSF stock have trended somewhat positive on Sunday, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BELLUS Health earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for BELLUS Health.
Who are some of BELLUS Health's key competitors?
Some companies that are related to BELLUS Health include The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), United Therapeutics (UTHR), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Emergent Biosolutions (EBS) and Alkermes (ALKS).
What other stocks do shareholders of BELLUS Health own?
Who are BELLUS Health's key executives?
BELLUS Health's management team includes the folowing people:
- Roberto Bellini, President, Chief Executive Officer & Director
- François Desjardins, Vice President-Finance
- Denis Garceau, Senior Vice President-Drug Development
- Tony Matzouranis, Vice President-Business Development
- Sébastien Roy, Secretary
How do I buy shares of BELLUS Health?
Shares of BLUSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
How big of a company is BELLUS Health?
What is BELLUS Health's official website?
How can I contact BELLUS Health?
BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at 45-0680-4500 or via email at [email protected]
MarketBeat Community Rating for BELLUS Health (OTCMKTS BLUSF)
| Community Ranking: | | 2.5 out of 5 (  ) |
| Outperform Votes: | | 49 (Thanks for Voting!) |
| Underperform Votes: | | 50 (Thanks for Voting!) |
| Total Votes: | | 99 |
